64
Views
0
CrossRef citations to date
0
Altmetric
Original Article

Comparison of conventional scoring systems versus MAGIC score to predict short-term mortality in patients hospitalized for alcoholic hepatitis

ORCID Icon, ORCID Icon, ORCID Icon & ORCID Icon
Pages 1318-1323 | Received 30 Jun 2020, Accepted 09 Sep 2020, Published online: 01 Oct 2020

References

  • Fung P, Pyrsopoulos N. Emerging concepts in alcoholic hepatitis. World J Hepatol. 2017;9(12):567–585.
  • Mathurin P, Duchatelle V, Ramond MJ, et al. Survival and prognostic factors in patients with severe alcoholic hepatitis treated with prednisolone. Gastroenterology. 1996;110(6):1847–1853.
  • Osna NA, Donohue TM, Jr, Kharbanda KK. Alcoholic liver disease: pathogenesis and current management. Alcohol Res. 2017;38(2):147–161.
  • Altamirano J, López-Pelayo H, Michelena J, et al. Alcohol abstinence in patients surviving an episode of alcoholic hepatitis: prediction and impact on long-term survival. Hepatology. 2017;66(6):1842–1853.
  • Anand AC, Garg HK. Approach to clinical syndrome of jaundice and encephalopathy in tropics. J Clin Exp Hepatol. 2015;5(Suppl 1):S116–S130.
  • Rahimi E, Pan JJ. Prognostic models for alcoholic hepatitis. Biomark Res. 2015;3:20
  • Frazier TH, Stocker AM, Kershner NA, Marsano LS, et al. Treatment of alcoholic liver disease. Therap Adv Gastroenterol. 2011;4(1):63–81.
  • Lafferty H, Stanley AJ, Forrest EH. The management of alcoholic hepatitis: a prospective comparison of scoring systems. Aliment Pharmacol Ther. 2013;38(6):603–610.
  • Dunn W, Jamil LH, Brown LS, et al. MELD accurately predicts mortality in patients with alcoholic hepatitis. Hepatology. 2005;41(2):353–358.
  • Forrest EH, Evans CDJ, Stewart S, et al. Analysis of factors predictive of mortality in alcoholic hepatitis and derivation and validation of the Glasgow alcoholic hepatitis score. Gut. 2005;54(8):1174–1179.
  • Dominguez M, Rincón D, Abraldes JG, et al. A new scoring system for prognostic stratification of patients with alcoholic hepatitis. Am J Gastroenterol. 2008;103(11):2747–2756.
  • Maddrey WC, Boitnott JK, Bedine MS, et al. Corticosteroid therapy of alcoholic hepatitis. Gastroenterology. 1978;75(2):193–199.
  • Pugh RN, Murray-Lyon IM, Dawson JL, et al. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg. 1973;60(8):646–649.
  • Mathurin P, Hadengue A, Bataller R, et al. EASL clinical practical guidelines: management of alcoholic liver disease. J Hepatol. 2012;57:399–420.
  • Lee M, Kim W, Choi Y, et al. Spontaneous evolution in bilirubin levels predicts liver-related mortality in patients with alcoholic hepatitis. PLoS One. 2014;9(7):e100870.
  • Thursz MR, Richardson P, Allison M, STOPAH Trial, et al. Prednisolone or pentoxifylline for alcoholic hepatitis. N Engl J Med. 2015;372(17):1619–1628.
  • Uno H, Cai T, Pencina MJ, et al. On the C-statistics for evaluating overall adequacy of risk prediction procedures with censored survival data. Stat Med. 2011;30(10):1105–1117.
  • Hothorn T, Zeileis A. Generalized maximally selected statistics. Biometrics. 2008;64(4):1263–1269.
  • Im GY, Cameron AM, Lucey MR. Liver transplantation for alcoholic hepatitis. J Hepatol. 2019;70(2):328–334.
  • Carithers RL, Herlong F, Diehl AM, et al. Methylprednisolone therapy in patients with severe alcoholic hepatitis. A randomized multicenter trial. Ann Intern Med. 1989;110(9):685–690.
  • Kulkarni K, Tran T, Medrano M, et al. The role of the discriminant factor in the assessment and treatment of alcoholic hepatitis. J Clin Gastroenterol. 2004;38(5):453–459.
  • Papastergiou V, Tsochatzis EA, Pieri G, et al. Nine scoring models for short-term mortality in alcoholic hepatitis: cross-validation in a biopsy-proven cohort. Aliment Pharmacol Ther. 2014;39(7):721–732.
  • Monsanto P, Almeida N, Lrias C, et al. Evaluation of MELD score and Maddrey discriminant function for mortality prediction in patients with alcoholic hepatitis. Hepatogastroenterology. 2013;60(125):1089–1094.
  • Naveau S, Giraud V, Borotto E, et al. Excess weight risk factor for alcoholic liver disease. Hepatology. 1997;25(1):108–111.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.